The Experts below are selected from a list of 64533 Experts worldwide ranked by ideXlab platform
Sundaram Ramakrishnan - One of the best experts on this subject based on the ideXlab platform.
-
Increased serum levels of Macrophage colony‐stimulating Factor in ovarian cancer
International Journal of Gynecology & Obstetrics, 1992Co-Authors: F-j Xu, Lee Daly, J. T. Soper, Sundaram Ramakrishnan, Andrew Berchuck, Daniel L. Clarke-pearson, Rc VastAbstract:Macrophage Colony-Stimulating Factor is a cytokine that stimulates proliferation and differentiation of phagocytic cells. Macrophage Colony-Stimulating Factor is produced by ovarian epithelial cancer cell lines and might provide a useful serum marker for the disease. Among sera from 69 patients with clinically apparent epithelial ovarian cancer, 47 (68%) had at least 2.5 ng/ ml Macrophage Colony-Stimulating Factor, whereas only two of 80 apparently healthy donors (2.5%) had a comparable elevation of Macrophage Colony-Stimulating Factor. Circulating levels of Macrophage Colony-Stimulating Factor did not correlate with serum levels of CA 125. Moreover, 14 of 25 ovarian cancer patients (56%) with clinically evident disease and normal levels of CA 125 «35 U/ml) had elevated levels of Macrophage Colony-Stimulating Factor. Among 29 patients with serum CA 125 levels < 35 U/ml before positive surgical surveillance procedures, 9 (31%) had at least 2.5 ng / ml Macrophage Colony-Stimulating Factor. Elevated levels of Macrophage Colony-Stimulating Factor were also found in patients with carcinomas from other primary sites and in 31 % of 134 patients with benign diseases. If intercurrent benign disease can be taken into account, Macrophage Colony-Stimulating Factor deserves further evaluation in combination with CA 125 in monitoring ovarian cancer. (AM J OBSTET GVNECOL 1991;165:1356-62.)
-
Serum levels of Macrophage Colony-Stimulating Factor in patients with ovarian cancer undergoing second-look laparotomy.
American Journal of Obstetrics and Gynecology, 1992Co-Authors: S A Elg, L F Carson, L L Adcock, L B Twiggs, K A Prem, Sundaram RamakrishnanAbstract:Objective: The purpose of this study was to evaluate the prognostic significance of Macrophage Colony-Stimulating Factor serum levels in patients with ovarian cancer undergoing second-look laparotomy. Study design: The presurgical serum levels of Macrophage Colony-Stimulating Factor from 33 consecutive patients with ovarian cancer undergoing second-look laparotomy were determined and compared with those of 50 healthy control subjects. Mean differences in groups were evaluated with the Student f test. Results: Sixteen of 33 patients had a positive result at second look and a mean serum Macrophage Colony-Stimulating Factor level of 2.31 ± 1.45 ng/ml. Seventeen of 33 patients had a negative result at second look and a mean Macrophage Colony-Stimulating Factor level of 1.90 ± 0.86 ng/ml ( p > 0.05). The mean Macrophage Colony-Stimulating Factor level in the control group was 1.20 ± 0.51 ng/ml. This was statistically lower than the mean level found in patients with a negative second-look result ( p Conclusion: Regardless of tumor status, serum Macrophage Colony-Stimulating Factor levels tend to be elevated at the time of second-look laparotomy.
-
Increased serum levels of Macrophage Colony-Stimulating Factor in ovarian cancer
American Journal of Obstetrics and Gynecology, 1991Co-Authors: Fengji Xu, Lee Daly, J. T. Soper, Sundaram Ramakrishnan, Andrew Berchuck, Daniel L. Clarke-pearson, Robert C. BastAbstract:Macrophage Colony-Stimulating Factor is a cytokine that stimulates proliferation and differentiation of phagocytic cells. Macrophage Colony-Stimulating Factor is produced by ovarian epithelial cancer cell lines and might provide a useful serum marker for the disease. Among sera from 69 patients with clinically apparent epithelial ovarian cancer, 47 (68%) had at least 2.5 ng/ml Macrophage Colony-Stimulating Factor, whereas only two of 80 apparently healthy donors (2.5%) had a comparable elevation of Macrophage Colony-Stimulating Factor. Circulating levels of Macrophage Colony-Stimulating Factor did not correlate with serum levels of CA 125. Moreover, 14 of 25 ovarian cancer patients (56%) with clinically evident disease and normal levels of CA 125 (
-
Increased serum levels of Macrophage Colony-Stimulating Factor in ovarian cancer.
American journal of obstetrics and gynecology, 1991Co-Authors: F-j Xu, Lee Daly, J. T. Soper, Sundaram Ramakrishnan, Andrew Berchuck, Daniel L. Clarke-pearson, Robert C. BastAbstract:Macrophage Colony-Stimulating Factor is a cytokine that stimulates proliferation and differentiation of phagocytic cells. Macrophage Colony-Stimulating Factor is produced by ovarian epithelial cancer cell lines and might provide a useful serum marker for the disease. Among sera from 69 patients with clinically apparent epithelial ovarian cancer, 47 (68%) had at least 2.5 ng/ml Macrophage Colony-Stimulating Factor, whereas only two of 80 apparently healthy donors (2.5%) had a comparable elevation of Macrophage Colony-Stimulating Factor. Circulating levels of Macrophage Colony-Stimulating Factor did not correlate with serum levels of CA 125. Moreover, 14 of 25 ovarian cancer patients (56%) with clinically evident disease and normal levels of CA 125 (less than 35 U/ml) had elevated levels of Macrophage Colony-Stimulating Factor. Among 29 patients with serum CA 125 levels less than 35 U/ml before positive surgical surveillance procedures, 9 (31%) had at least 2.5 ng/ml Macrophage Colony-Stimulating Factor. Elevated levels of Macrophage Colony-Stimulating Factor were also found in patients with carcinomas from other primary sites and in 31% of 134 patients with benign diseases. If intercurrent benign disease can be taken into account, Macrophage Colony-Stimulating Factor deserves further evaluation in combination with CA 125 in monitoring ovarian cancer.
S A Elg - One of the best experts on this subject based on the ideXlab platform.
-
Serum levels of Macrophage Colony-Stimulating Factor in patients with ovarian cancer undergoing second-look laparotomy.
American journal of obstetrics and gynecology, 1992Co-Authors: S A Elg, L F Carson, L L Adcock, L B Twiggs, K A Prem, S. RamakrishnanAbstract:The purpose of this study was to evaluate the prognostic significance of Macrophage Colony-Stimulating Factor serum levels in patients with ovarian cancer undergoing second-look laparotomy. The presurgical serum levels of Macrophage Colony-Stimulating Factor from 33 consecutive patients with ovarian cancer undergoing second-look laparotomy were determined and compared with those of 50 healthy control subjects. Mean differences in groups were evaluated with the Student t test. Sixteen of 33 patients had a positive result at second look and a mean serum Macrophage Colony-Stimulating Factor level of 2.31 +/- 1.45 ng/ml. Seventeen of 33 patients had a negative result at second look and a mean Macrophage Colony-Stimulating Factor level of 1.90 +/- 0.86 ng/ml (p greater than 0.05). The mean Macrophage Colony-Stimulating Factor level in the control group was 1.20 +/- 0.51 ng/ml. This was statistically lower than the mean level found in patients with a negative second-look result (p less than 0.05). Regardless of tumor status, serum Macrophage Colony-Stimulating Factor levels tend to be elevated at the time of second-look laparotomy.
-
Serum levels of Macrophage Colony-Stimulating Factor in patients with ovarian cancer undergoing second-look laparotomy.
American Journal of Obstetrics and Gynecology, 1992Co-Authors: S A Elg, L F Carson, L L Adcock, L B Twiggs, K A Prem, Sundaram RamakrishnanAbstract:Objective: The purpose of this study was to evaluate the prognostic significance of Macrophage Colony-Stimulating Factor serum levels in patients with ovarian cancer undergoing second-look laparotomy. Study design: The presurgical serum levels of Macrophage Colony-Stimulating Factor from 33 consecutive patients with ovarian cancer undergoing second-look laparotomy were determined and compared with those of 50 healthy control subjects. Mean differences in groups were evaluated with the Student f test. Results: Sixteen of 33 patients had a positive result at second look and a mean serum Macrophage Colony-Stimulating Factor level of 2.31 ± 1.45 ng/ml. Seventeen of 33 patients had a negative result at second look and a mean Macrophage Colony-Stimulating Factor level of 1.90 ± 0.86 ng/ml ( p > 0.05). The mean Macrophage Colony-Stimulating Factor level in the control group was 1.20 ± 0.51 ng/ml. This was statistically lower than the mean level found in patients with a negative second-look result ( p Conclusion: Regardless of tumor status, serum Macrophage Colony-Stimulating Factor levels tend to be elevated at the time of second-look laparotomy.
Robert C. Bast - One of the best experts on this subject based on the ideXlab platform.
-
Preoperative evaluation of Macrophage Colony-Stimulating Factor levels in patients with endometrial cancer
American Journal of Obstetrics and Gynecology, 1996Co-Authors: J. T. Soper, Fenji Xu, Richard K. Dodge, Andrew Berchuck, S. Ramakrishnan, Daniel L. Clarke-pearson, Robert C. BastAbstract:Abstract OBJECTIVE: Our purpose was to examine the relationship between preoperative serum levels of Macrophage Colony-Stimulating Factor, alone and in combination with CA 125, and the presence of prognostic clinicopathologic Factors and subclinical metastases in women with endometrial cancer. STUDY DESIGN: Ninety-two women who underwent primary exploration for endometrial adenocarcinoma had preoperative serum samples evaluated for Macrophage Colony-Stimulating Factor and CA 125 levels. Multivariate analysis was used to determine the associations of surgicopathologic findings with Macrophage Colony-Stimulating Factor and CA 125 levels. Logistic regression analysis was used to identify Factors associated with the risk of extrauterine disease. The association of Macrophage Colony-Stimulating Factor and CA 125 levels with stage, grade, and depth of myometrial invasion and histologic characteristics were analyzed with Fisher's two-tailed exact test. RESULTS: Elevated levels of Macrophage Colony-Stimulating Factor were not associated with depth of myometrial invasion, histologic grade, or histologic cell type; however, advanced stage (p = 0.02) and the presence of lymph node metastases (p = 0.04) were associated with elevated levels. Sensitivity and specificity of Macrophage Colony-Stimulating Factor for predicting extrauterine disease were 42% and 89%, respectively. If either an elevated Macrophage Colony-Stimulating Factor or an elevated CA 125 level was used to predict extrauterine disease, the sensitivity was increased to 67% but the specificity was decreased to 78%. Macrophage Colony-Stimulating Factor elevations predicted lymph node metastases with a sensitivity of 50% and a specificity of 86%. A multivariate regression model showed CA 125 to be the most significant predictor of extrauterine disease; Macrophage Colony-Stimulating Factor also contributed prognostic information (p = 0.02). The sensitivity and specificity of the multivariate model for predicting extrauterine disease were 75% and 73%, respectively. CONCLUSION: Macrophage Colony-Stimulating Factor and CA 125 are neither sensitive nor specific enough to be used as predictors of the presence or absence of extrauterine disease in patients with endometrial cancer. (AM J OBSTET GYNECOL 1996;174:1316-9.)
-
Increased serum levels of Macrophage Colony-Stimulating Factor in ovarian cancer
American Journal of Obstetrics and Gynecology, 1991Co-Authors: Fengji Xu, Lee Daly, J. T. Soper, Sundaram Ramakrishnan, Andrew Berchuck, Daniel L. Clarke-pearson, Robert C. BastAbstract:Macrophage Colony-Stimulating Factor is a cytokine that stimulates proliferation and differentiation of phagocytic cells. Macrophage Colony-Stimulating Factor is produced by ovarian epithelial cancer cell lines and might provide a useful serum marker for the disease. Among sera from 69 patients with clinically apparent epithelial ovarian cancer, 47 (68%) had at least 2.5 ng/ml Macrophage Colony-Stimulating Factor, whereas only two of 80 apparently healthy donors (2.5%) had a comparable elevation of Macrophage Colony-Stimulating Factor. Circulating levels of Macrophage Colony-Stimulating Factor did not correlate with serum levels of CA 125. Moreover, 14 of 25 ovarian cancer patients (56%) with clinically evident disease and normal levels of CA 125 (
-
Increased serum levels of Macrophage Colony-Stimulating Factor in ovarian cancer.
American journal of obstetrics and gynecology, 1991Co-Authors: F-j Xu, Lee Daly, J. T. Soper, Sundaram Ramakrishnan, Andrew Berchuck, Daniel L. Clarke-pearson, Robert C. BastAbstract:Macrophage Colony-Stimulating Factor is a cytokine that stimulates proliferation and differentiation of phagocytic cells. Macrophage Colony-Stimulating Factor is produced by ovarian epithelial cancer cell lines and might provide a useful serum marker for the disease. Among sera from 69 patients with clinically apparent epithelial ovarian cancer, 47 (68%) had at least 2.5 ng/ml Macrophage Colony-Stimulating Factor, whereas only two of 80 apparently healthy donors (2.5%) had a comparable elevation of Macrophage Colony-Stimulating Factor. Circulating levels of Macrophage Colony-Stimulating Factor did not correlate with serum levels of CA 125. Moreover, 14 of 25 ovarian cancer patients (56%) with clinically evident disease and normal levels of CA 125 (less than 35 U/ml) had elevated levels of Macrophage Colony-Stimulating Factor. Among 29 patients with serum CA 125 levels less than 35 U/ml before positive surgical surveillance procedures, 9 (31%) had at least 2.5 ng/ml Macrophage Colony-Stimulating Factor. Elevated levels of Macrophage Colony-Stimulating Factor were also found in patients with carcinomas from other primary sites and in 31% of 134 patients with benign diseases. If intercurrent benign disease can be taken into account, Macrophage Colony-Stimulating Factor deserves further evaluation in combination with CA 125 in monitoring ovarian cancer.
S. Ramakrishnan - One of the best experts on this subject based on the ideXlab platform.
-
Preoperative evaluation of Macrophage Colony-Stimulating Factor levels in patients with endometrial cancer
American Journal of Obstetrics and Gynecology, 1996Co-Authors: J. T. Soper, Fenji Xu, Richard K. Dodge, Andrew Berchuck, S. Ramakrishnan, Daniel L. Clarke-pearson, Robert C. BastAbstract:Abstract OBJECTIVE: Our purpose was to examine the relationship between preoperative serum levels of Macrophage Colony-Stimulating Factor, alone and in combination with CA 125, and the presence of prognostic clinicopathologic Factors and subclinical metastases in women with endometrial cancer. STUDY DESIGN: Ninety-two women who underwent primary exploration for endometrial adenocarcinoma had preoperative serum samples evaluated for Macrophage Colony-Stimulating Factor and CA 125 levels. Multivariate analysis was used to determine the associations of surgicopathologic findings with Macrophage Colony-Stimulating Factor and CA 125 levels. Logistic regression analysis was used to identify Factors associated with the risk of extrauterine disease. The association of Macrophage Colony-Stimulating Factor and CA 125 levels with stage, grade, and depth of myometrial invasion and histologic characteristics were analyzed with Fisher's two-tailed exact test. RESULTS: Elevated levels of Macrophage Colony-Stimulating Factor were not associated with depth of myometrial invasion, histologic grade, or histologic cell type; however, advanced stage (p = 0.02) and the presence of lymph node metastases (p = 0.04) were associated with elevated levels. Sensitivity and specificity of Macrophage Colony-Stimulating Factor for predicting extrauterine disease were 42% and 89%, respectively. If either an elevated Macrophage Colony-Stimulating Factor or an elevated CA 125 level was used to predict extrauterine disease, the sensitivity was increased to 67% but the specificity was decreased to 78%. Macrophage Colony-Stimulating Factor elevations predicted lymph node metastases with a sensitivity of 50% and a specificity of 86%. A multivariate regression model showed CA 125 to be the most significant predictor of extrauterine disease; Macrophage Colony-Stimulating Factor also contributed prognostic information (p = 0.02). The sensitivity and specificity of the multivariate model for predicting extrauterine disease were 75% and 73%, respectively. CONCLUSION: Macrophage Colony-Stimulating Factor and CA 125 are neither sensitive nor specific enough to be used as predictors of the presence or absence of extrauterine disease in patients with endometrial cancer. (AM J OBSTET GYNECOL 1996;174:1316-9.)
-
Serum levels of Macrophage Colony-Stimulating Factor in patients with ovarian cancer undergoing second-look laparotomy.
American journal of obstetrics and gynecology, 1992Co-Authors: S A Elg, L F Carson, L L Adcock, L B Twiggs, K A Prem, S. RamakrishnanAbstract:The purpose of this study was to evaluate the prognostic significance of Macrophage Colony-Stimulating Factor serum levels in patients with ovarian cancer undergoing second-look laparotomy. The presurgical serum levels of Macrophage Colony-Stimulating Factor from 33 consecutive patients with ovarian cancer undergoing second-look laparotomy were determined and compared with those of 50 healthy control subjects. Mean differences in groups were evaluated with the Student t test. Sixteen of 33 patients had a positive result at second look and a mean serum Macrophage Colony-Stimulating Factor level of 2.31 +/- 1.45 ng/ml. Seventeen of 33 patients had a negative result at second look and a mean Macrophage Colony-Stimulating Factor level of 1.90 +/- 0.86 ng/ml (p greater than 0.05). The mean Macrophage Colony-Stimulating Factor level in the control group was 1.20 +/- 0.51 ng/ml. This was statistically lower than the mean level found in patients with a negative second-look result (p less than 0.05). Regardless of tumor status, serum Macrophage Colony-Stimulating Factor levels tend to be elevated at the time of second-look laparotomy.
L F Carson - One of the best experts on this subject based on the ideXlab platform.
-
Serum levels of Macrophage Colony-Stimulating Factor in patients with ovarian cancer undergoing second-look laparotomy.
American journal of obstetrics and gynecology, 1992Co-Authors: S A Elg, L F Carson, L L Adcock, L B Twiggs, K A Prem, S. RamakrishnanAbstract:The purpose of this study was to evaluate the prognostic significance of Macrophage Colony-Stimulating Factor serum levels in patients with ovarian cancer undergoing second-look laparotomy. The presurgical serum levels of Macrophage Colony-Stimulating Factor from 33 consecutive patients with ovarian cancer undergoing second-look laparotomy were determined and compared with those of 50 healthy control subjects. Mean differences in groups were evaluated with the Student t test. Sixteen of 33 patients had a positive result at second look and a mean serum Macrophage Colony-Stimulating Factor level of 2.31 +/- 1.45 ng/ml. Seventeen of 33 patients had a negative result at second look and a mean Macrophage Colony-Stimulating Factor level of 1.90 +/- 0.86 ng/ml (p greater than 0.05). The mean Macrophage Colony-Stimulating Factor level in the control group was 1.20 +/- 0.51 ng/ml. This was statistically lower than the mean level found in patients with a negative second-look result (p less than 0.05). Regardless of tumor status, serum Macrophage Colony-Stimulating Factor levels tend to be elevated at the time of second-look laparotomy.
-
Serum levels of Macrophage Colony-Stimulating Factor in patients with ovarian cancer undergoing second-look laparotomy.
American Journal of Obstetrics and Gynecology, 1992Co-Authors: S A Elg, L F Carson, L L Adcock, L B Twiggs, K A Prem, Sundaram RamakrishnanAbstract:Objective: The purpose of this study was to evaluate the prognostic significance of Macrophage Colony-Stimulating Factor serum levels in patients with ovarian cancer undergoing second-look laparotomy. Study design: The presurgical serum levels of Macrophage Colony-Stimulating Factor from 33 consecutive patients with ovarian cancer undergoing second-look laparotomy were determined and compared with those of 50 healthy control subjects. Mean differences in groups were evaluated with the Student f test. Results: Sixteen of 33 patients had a positive result at second look and a mean serum Macrophage Colony-Stimulating Factor level of 2.31 ± 1.45 ng/ml. Seventeen of 33 patients had a negative result at second look and a mean Macrophage Colony-Stimulating Factor level of 1.90 ± 0.86 ng/ml ( p > 0.05). The mean Macrophage Colony-Stimulating Factor level in the control group was 1.20 ± 0.51 ng/ml. This was statistically lower than the mean level found in patients with a negative second-look result ( p Conclusion: Regardless of tumor status, serum Macrophage Colony-Stimulating Factor levels tend to be elevated at the time of second-look laparotomy.
